PTPRC and neoplasm: Spatial transcriptomic (i.e., CTA) data was used to estimate the relative fraction of immune cell types across 12 ROIs of CD45+ tumor and 12 ROIs of CD45+ TAS from prostate cancer patients using CIBERSORTx [57,58].